Onconetix Stock Current Valuation
| ONCO Stock | USD 0.80 0.29 26.61% |
Valuation analysis of Onconetix helps investors to measure Onconetix's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of the 26th of November 2024, Enterprise Value Over EBITDA is likely to drop to -4.03. In addition to that, Enterprise Value Multiple is likely to drop to -4.03. Fundamental drivers impacting Onconetix's valuation include:
Price Book 0.3058 | Enterprise Value 23.4 M | Enterprise Value Ebitda (0.47) | Price Sales 4.5334 | Enterprise Value Revenue 15.979 |
Undervalued
Today
Please note that Onconetix's price fluctuation is extremely dangerous at this time. Calculation of the real value of Onconetix is based on 3 months time horizon. Increasing Onconetix's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Onconetix is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Onconetix Stock. However, Onconetix's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.8 | Real 2.84 | Target 9.0 | Hype 0.53 | Naive 1.73 |
The intrinsic value of Onconetix's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Onconetix's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Onconetix helps investors to forecast how Onconetix stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Onconetix more accurately as focusing exclusively on Onconetix's fundamentals will not take into account other important factors: Onconetix Company Current Valuation Analysis
Onconetix's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Onconetix Current Valuation | 23.39 M |
Most of Onconetix's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Onconetix is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Onconetix Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Onconetix is extremely important. It helps to project a fair market value of Onconetix Stock properly, considering its historical fundamentals such as Current Valuation. Since Onconetix's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Onconetix's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Onconetix's interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Onconetix has a Current Valuation of 23.39 M. This is 99.84% lower than that of the Biotechnology sector and 99.5% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.86% higher than that of the company.
Onconetix Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Onconetix's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Onconetix could also be used in its relative valuation, which is a method of valuing Onconetix by comparing valuation metrics of similar companies.Onconetix is currently under evaluation in current valuation category among its peers.
Onconetix Fundamentals
| Return On Equity | -17.58 | ||||
| Return On Asset | -0.22 | ||||
| Operating Margin | (3.00) % | ||||
| Current Valuation | 23.39 M | ||||
| Shares Outstanding | 8.29 M | ||||
| Shares Owned By Insiders | 57.93 % | ||||
| Shares Owned By Institutions | 7.86 % | ||||
| Number Of Shares Shorted | 21.7 K | ||||
| Price To Book | 0.31 X | ||||
| Price To Sales | 4.53 X | ||||
| Revenue | 58.47 K | ||||
| EBITDA | (36.71 M) | ||||
| Net Income | (37.41 M) | ||||
| Cash And Equivalents | 113.36 K | ||||
| Cash Per Share | 0.85 X | ||||
| Total Debt | 9.89 M | ||||
| Current Ratio | 0.62 X | ||||
| Book Value Per Share | (64.14) X | ||||
| Cash Flow From Operations | (13.58 M) | ||||
| Short Ratio | 0.23 X | ||||
| Earnings Per Share | (109.20) X | ||||
| Target Price | 9.0 | ||||
| Number Of Employees | 12 | ||||
| Beta | 3.73 | ||||
| Market Capitalization | 6.64 M | ||||
| Total Asset | 88.82 M | ||||
| Retained Earnings | (56.79 M) | ||||
| Working Capital | (11.35 M) | ||||
| Net Asset | 88.82 M |
About Onconetix Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Onconetix's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Onconetix using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Onconetix based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Onconetix
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Onconetix position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Onconetix will appreciate offsetting losses from the drop in the long position's value.Moving together with Onconetix Stock
| 0.63 | A | Agilent Technologies | PairCorr |
| 0.72 | ME | 23Andme Holding | PairCorr |
| 0.75 | VALN | Valneva SE ADR | PairCorr |
| 0.82 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
Moving against Onconetix Stock
| 0.75 | MDGL | Madrigal Pharmaceuticals | PairCorr |
| 0.63 | RNXT | RenovoRx | PairCorr |
| 0.39 | KEP | Korea Electric Power | PairCorr |
| 0.38 | NXGLW | NexGel Warrant | PairCorr |
The ability to find closely correlated positions to Onconetix could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Onconetix when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Onconetix - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Onconetix to buy it.
The correlation of Onconetix is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Onconetix moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Onconetix moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Onconetix can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Onconetix Piotroski F Score and Onconetix Altman Z Score analysis. To learn how to invest in Onconetix Stock, please use our How to Invest in Onconetix guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Onconetix. If investors know Onconetix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Onconetix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (109.20) | Revenue Per Share 2.892 | Return On Assets (0.22) | Return On Equity (17.58) |
The market value of Onconetix is measured differently than its book value, which is the value of Onconetix that is recorded on the company's balance sheet. Investors also form their own opinion of Onconetix's value that differs from its market value or its book value, called intrinsic value, which is Onconetix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Onconetix's market value can be influenced by many factors that don't directly affect Onconetix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Onconetix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Onconetix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Onconetix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.